These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 16350429

  • 1. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.
    Patton JF, Sullivan T, Mun Y, Reeves T, Rossi G, Wallace JF.
    J Support Oncol; 2005; 3(6):419-26. PubMed ID: 16350429
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS, Rocconi RP, Kilgore LC, Barnes MN.
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
    Voils SA, Harpe SH, Brophy GM.
    Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
    [Abstract] [Full Text] [Related]

  • 6. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.
    Horowitz J, Agarwal A, Huang F, Gitlin M, Gandra SR, Cangialose CB.
    J Manag Care Pharm; 2009 Apr; 15(9):741-50. PubMed ID: 19954265
    [Abstract] [Full Text] [Related]

  • 7. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R.
    Clin Ther; 2003 Nov; 25(11):2781-96. PubMed ID: 14693304
    [Abstract] [Full Text] [Related]

  • 8. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M, García Hernández MA, Navarro MJ, Pérez Silva F, Cacho M, De Gracia MC.
    Nefrologia; 2004 Nov; 24(1):54-9. PubMed ID: 15083958
    [Abstract] [Full Text] [Related]

  • 9. Clinical outcomes associated with conversion from epoetin alfa to darbepoetin alfa in hospitalized hemodialysis patients.
    Sarac E, Chikyarappa A, Sabol B, Gemmel D, Globe D, Barlev A, Audhya P.
    Am J Nephrol; 2006 Nov; 26(6):571-8. PubMed ID: 17170523
    [Abstract] [Full Text] [Related]

  • 10. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
    Nurko S, Spirko R, Law A, Dennis VW.
    Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase III clinical trials with darbepoetin: implications for clinicians.
    Glaspy J.
    Best Pract Res Clin Haematol; 2005 Sep; 18(3):407-16. PubMed ID: 15792914
    [Abstract] [Full Text] [Related]

  • 13. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
    Hoggard J, Crouch T, McMurray S, Levine M, Prathikanti R, Scarlata D, Audhya P.
    Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
    [Abstract] [Full Text] [Related]

  • 14. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
    Brophy GM, Sheehan V, Shapiro MJ, Lottenberg L, Scarlata D, Audhya P, ASSESS Study Group and Amgen Inc.
    Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
    [Abstract] [Full Text] [Related]

  • 15. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response.
    Villegas A, Arrizabalaga B, Fernández-Lago C, Castro M, Mayans JR, González-Porras JR, Duarte RF, Remacha AF, Luño E, Gasquet JA.
    Curr Med Res Opin; 2011 May; 27(5):951-60. PubMed ID: 21381892
    [Abstract] [Full Text] [Related]

  • 16. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ, Jacobson DR.
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD, Radeva JI, Daniel DB, Mody SH, Forlenza JB, McKenzie RS, Schulman KA.
    Pharmacoeconomics; 2006 Jan; 24(5):479-94. PubMed ID: 16706573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.